文献速递慢性肾脏病肾移植

老年活体肾捐献者合并高血压的终末期肾病风险

Risk of ESKD in Older Live Kidney Donors with Hypertension.
PubMed 文献 · Clin J Am Soc Nephrol · 2019-06-25

该美国队列研究纳入1999至2016年24533名老年(≥50岁)活体肾捐献者,其中2265名捐献前有高血压。随访中位7.1年,高血压组15年ESKD风险为0.8%,显著高于无高血压组的0.2%(调整HR 3.04,95%CI 1.28-7.22,P=0.01),但绝对风险低,且15年死亡率无显著差异。

要点

  • 老年高血压捐献者15年ESKD绝对风险仅0.8%,但相对风险为无高血压者的3.04倍。
  • 使用降压药的捐献者ESKD风险为未使用者的6.21倍(95%CI 1.20-32.17)。
  • 捐献前高血压与15年死亡率无显著关联(HR 1.18,95%CI 0.84-1.66)。

核心结论

  • 老年高血压捐献者较无高血压者15年ESKD风险升高但绝对风险低,死亡率无显著差异。

研究设计与样本

  • 美国队列研究,纳入1999-2016年24533名≥50岁活体肾捐献者,其中2265名有捐献前高血压。

主要发现

  • 高血压组15年ESKD风险0.8%(95%CI 0.4-1.6),无高血压组0.2%(95%CI 0.1-0.4),调整HR 3.04(95%CI 1.28-7.22,P=0.01)。
  • 使用降压药者ESKD风险为未使用者6.21倍(95%CI 1.20-32.17,P=0.03)。
  • 高血压与15年死亡率无显著关联(HR 1.18,95%CI 0.84-1.66,P=0.34)。

关键数值与推荐

  • 2004-2016年高血压定义为捐献前使用降压药;1999-2003年定义为收缩压≥140或舒张压≥90 mm Hg。

临床怎么用

  • 老年高血压捐献者ESKD绝对风险低,但需个体化评估,尤其关注使用降压药者。

局限性

  • 随访中位仅7.1年,ESKD事件数少(24例),可能影响长期风险估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Hypertension in older kidney donor candidates is viewed as safe. However, hypertension guidelines have evolved and long-term outcomes have not been explored. We sought to quantify the 15-year risk of ESKD and mortality in older donors (≥50 years old) with versus those without hypertension. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A United States cohort of 24,533 older donors from 1999 to 2016, including 2265 with predonation hypertension, were linked to Centers for Medicare and Medicaid Services data and the Social Security Death Master File to ascertain ESKD development and mortality. The exposure of interest was predonation hypertension. From 2004 to 2016, hypertension was defined as documented predonation use of antihypertensive therapy, regardless of systolic BP or diastolic BP; from 1999 to 2003, when there was no documentation of antihypertensive therapy, hypertension was defined as predonation systolic BP ≥140 or diastolic BP ≥90 mm Hg. RESULTS: Older donors were 82% white, 6% black, 7% Hispanic, and 3% Asian. The median follow-up was 7.1 years (interquartile range, 3.4-11.1; maximum, 18). There were 24 ESKD and 252 death events during the study period. The 15-year risk of ESKD was 0.8% (95% confidence interval [95% CI], 0.4 to 1.6) for donors with hypertension (mean systolic BP, 138 mm Hg) versus 0.2% (95% CI, 0.1 to 0.4) for donors without hypertension (mean systolic BP, 123 mm Hg; adjusted hazard ratio, 3.04; 95% CI, 1.28 to 7.22; P=0.01). When predonation antihypertensive therapy was available, the risk of ESKD was 6.21-fold higher (95% CI, 1.20 to 32.17; P=0.03) for donors using antihypertensive therapy (mean systolic BP, 132 mm Hg) versus those not using antihypertensive therapy (mean systolic BP, 124 mm Hg). There was no significant association between donor hypertension and 15-year mortality (hazard ratio, 1.18; 95% CI, 0.84 to 1.66; P=0.34). CONCLUSIONS: Compared with older donors without hypertension, older donors with hypertension had higher risk of ESKD, but not mortality, for 15 years postdonation. However, the absolute risk of ESKD was small.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Al Ammary F, Luo X, Muzaale AD, et al. Risk of ESKD in Older Live Kidney Donors with Hypertension. Clin J Am Soc Nephrol. 2019. PMID: 31239252. doi:10.2215/CJN.14031118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。